Summary

The global biologics safety testing market is estimated to reach USD 9.66 billion by 2031 from USD 5.57 billion in 2026, at a CAGR of 11.6% during the forecast period of 2026 to 2031. The global biologics safety testing market is projected to witness strong growth over the forecast period, supported by the rising biologics and biosimilars pipeline and the growth of advanced modalities such as cell & gene therapies and mRNA products. Market estimates from published industry sources indicate robust growth through 2031, driven by strong expansion in biologics development and manufacturing, as well as rising demand for stringent safety testing to ensure product quality. However, the high cost of advanced testing equipment, limited specialized expertise, and regulatory divergence across regions are expected to remain key factors restraining broader market expansion.

https://mnmimg.marketsandmarkets.com/Images/biologics-safety-testing-market-img-overview.webp

“The assays, kits, and reagents segment accounted for the largest share by product in the biologics safety testing market in 2025.”
Based on product, the biologics safety testing market is broadly segmented into assays, kits & reagents, and instruments. In 2025, assays, kits, and reagents accounted for the largest share of the biologics safety testing market, driven by their widespread use in routine applications such as endotoxin, mycoplasma, sterility, and viral detection testing. Their ease of use, reliability, and compatibility with automated and high-throughput systems make them essential across laboratories. Additionally, their cost-effectiveness and ability to deliver rapid, reproducible results support consistent demand from biopharmaceutical companies, CROs, and research institutions globally.
?
“The monoclonal antibodies and therapeutic proteins segment accounted for the largest share of the biologics safety testing product applications market in 2025.”
Based on application, the global biologics safety testing product market is segmented into vaccines, monoclonal antibodies & therapeutic proteins, cellular & gene therapy products, blood & blood products, and other applications. The monoclonal antibodies & therapeutic proteins segment accounted for the largest share of the biologics safety testing product market in 2025, driven by their extensive use in treating chronic and complex diseases. The growing pipeline, increasing approvals, and large-scale commercial production of these biologics require rigorous safety testing. Additionally, stringent regulatory requirements and the need to ensure product purity, potency, and consistency further contribute to the segment’s market position globally.
“The Asia Pacific is growing at the highest CAGR in the biologics safety testing market from 2026 to 2031.”
The biologics safety testing market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. During the forecast period, the Asia Pacific region is estimated to grow at the highest CAGR, supported by expanding biopharmaceutical manufacturing, increasing adoption of biologics and biosimilars, and rising clinical trial activity. Growth is further driven by improving regulatory frameworks, and the presence of key regional and global players such as Samsung Biologics and WuXi AppTec is actively strengthening biologics development and safety testing capabilities.

The primary interviews conducted for this report can be categorized as follows:

? By Respondent: Supply Side - 70% and Demand Side - 30%
? By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
? By Designation: CXOs and Directors - 30%, Managers - 45%, and Others - 25%
? By Region: North America - 40%, Europe - 25%, Asia Pacific - 20%, Latin America - 10%, and the Middle East - 5%


List of Companies Profiled in the Report
? Thermo Fisher Scientific Inc.
? Merck KGaA
? Lonza
? FUJIFILM Corporation
? Sartorius AG
? F. Hoffmann- La Roche Ltd.
? Charles River Laboratories
? bioM?rieux
? WuXi AppTec
? SGS Soci?t? G?n?rale de Surveillance SA
? Sotera Health
? Samsung Biologics
? GenScript
? Agilent Technologies, Inc.
? Syngene International Limited
? Eurofins Scientific
? Laboratory Corporation of America Holdings
? Bio-Rad Laboratories, Inc.
? QIAGEN

Research Coverage
This research report categorizes the biologics safety testing market by offering, by test type, by application (product & service applications), by end user (product & service end users), and by region. The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the biologics safety testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product and service approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the biologics safety testing market. This report covers competitive analysis of top players and upcoming startups in the biologics safety testing market ecosystem.
Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing the closest approximations of revenue for the overall biologics safety testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
? Analysis of key drivers (rising biologics and biosimilars pipeline, stringent and evolving regulatory requirements, growth of advanced modalities like cell & gene therapies and mRNA products, expansion of CDMOs and the structural shift toward outsourced testing), restraints (high cost of advanced testing equipment and limited specialized expertise, regulatory divergence across regions), opportunities (growing focus on next-generation therapeutics, the shift toward animal-free testing approaches) and challenges (assay standardization gap) influencing the growth of biologics safety testing market
? Product Development/Innovation: Detailed insights on newly launched products of the biologics safety testing market
? Market Development: Comprehensive information about lucrative markets ? the report analyses the biologics safety testing market across varied regions
? Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biologics safety testing market
? Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Lonza (Switzerland), FUJIFILM Corporation (Japan), Sartorius AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), and Charles River Laboratories (US), among others

ページTOPに戻る

Table of Contents

1 INTRODUCTION 46
1.1 STUDY OBJECTIVES 46
1.2 MARKET DEFINITION 46
1.2.1 INCLUSIONS & EXCLUSIONS 47
1.3 MARKET SCOPE 48
1.3.1 MARKETS COVERED 48
1.3.2 YEARS CONSIDERED 49
1.3.3 CURRENCY CONSIDERED 49
1.4 STAKEHOLDERS 49
1.5 SUMMARY OF CHANGES 50
2 EXECUTIVE SUMMARY 51
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 51
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 52
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 53
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 54
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 55
3 PREMIUM INSIGHTS 57
3.1 BIOLOGICS SAFETY TESTING MARKET OVERVIEW 57
3.2 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING & REGION 58
3.3 BIOLOGICS SAFETY TESTING MARKET: GEOGRAPHIC SNAPSHOT 59
4 MARKET OVERVIEW 60
4.1 INTRODUCTION 60
4.2 MARKET DYNAMICS 60
4.2.1 DRIVERS 61
4.2.1.1 Rising biologics and biosimilars pipeline 61
4.2.1.2 Stringent and evolving regulatory requirements 62
4.2.1.3 Growth of advanced modalities like cell & gene therapies and mRNA products 62
4.2.1.4 Rising demand for outsourced development/manufacturing and testing 62
4.2.2 RESTRAINTS 63
4.2.2.1 High cost of advanced testing equipment and limited specialized expertise 63
4.2.2.2 Regulatory divergence across regions 63
4.2.3 OPPORTUNITIES 64
4.2.3.1 Growing focus on next-generation therapeutics 64
4.2.3.2 Shift toward animal-free testing approaches 64
4.2.4 CHALLENGES 65
4.2.4.1 Assay standardization gap 65
4.3 UNMET NEEDS AND WHITE SPACES 65
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 65
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 66
5 INDUSTRY TRENDS 67
5.1 PORTER’S FIVE FORCES ANALYSIS 67
5.1.1 THREAT OF NEW ENTRANTS 68
5.1.2 THREAT OF SUBSTITUTES 68
5.1.3 BARGAINING POWER OF BUYERS 68
5.1.4 BARGAINING POWER OF SUPPLIERS 68
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 68
5.2 MACROECONOMIC OUTLOOK 69
5.2.1 INTRODUCTION 69
5.2.2 GDP TRENDS AND FORECAST 69
5.2.3 TRENDS IN GLOBAL BIOLOGICS SAFETY TESTING MARKET 70
5.3 VALUE CHAIN ANALYSIS 70
5.4 ECOSYSTEM ANALYSIS 72
5.5 PRICING ANALYSIS 74
5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023?2025 75
5.5.2 INDICATIVE SELLING PRICE, BY REGION, 2025 76
5.6 KEY CONFERENCES & EVENTS 77
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 78
5.8 INVESTMENT/FUNDING ACTIVITY 79
5.9 IMPACT OF US TARIFFS?BIOLOGICS SAFETY TESTING MARKET 80
5.9.1 INTRODUCTION 80
5.9.2 KEY TARIFF RATES 80
5.9.3 PRICE IMPACT ANALYSIS 81
5.9.4 IMPACT ON COUNTRIES/REGIONS 82
5.9.4.1 North America 82
5.9.4.2 Europe 82
5.9.4.3 Asia Pacific 82
5.9.5 IMPACT ON END-USE INDUSTRIES 83
5.9.5.1 Pharmaceutical and biotechnology companies 83
5.9.5.2 CROs & CDMOs 83
5.9.5.3 Academic & Research Institutes 84
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 85
6.1 KEY TECHNOLOGIES 85
6.1.1 POLYMERASE CHAIN REACTION (PCR) 85
6.1.2 NEXT-GENERATION SEQUENCING (NGS) 86
6.2 ADJACENT TECHNOLOGIES 86
6.2.1 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY 86
6.3 COMPLEMENTARY TECHNOLOGIES 86
6.3.1 LAB-ON-A-CHIP (LOC) SYSTEMS 86
6.3.2 HIGH-CONTENT SCREENING (HCS) 87
6.4 TECHNOLOGY/PRODUCT ROADMAP 87
6.5 PATENT ANALYSIS 88
6.5.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR BIOLOGICS SAFETY TESTING PATENTS, 2015?2025 88
6.6 FUTURE APPLICATIONS 89
6.7 IMPACT OF AI/GEN AI ON BIOLOGICS SAFETY TESTING MARKET 89
6.7.1 TOP USE CASES AND MARKET POTENTIAL 90
6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN BIOLOGICS SAFETY TESTING MARKET 91
6.7.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 91
6.7.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN BIOLOGICS SAFETY TESTING MARKET 92
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 93
7.1 REGIONAL REGULATIONS AND COMPLIANCE 93
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
7.1.2 REGULATORY FRAMEWORK 97
7.1.3 INDUSTRY STANDARDS 99
7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 99
7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 100
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 102
8.1 DECISION-MAKING PROCESS 102
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 103
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 103
8.2.2 KEY BUYING CRITERIA 104
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 105
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 106
8.5 MARKET PROFITABILITY 106
9 BIOLOGICS SAFETY TESTING MARKET, BY OFFERING 107
9.1 INTRODUCTION 108
9.2 SERVICES 108
9.2.1 VIRUS SAFETY TESTING SERVICES 112
9.2.1.1 Rising focus on development of advanced therapies to drive growth 112
9.2.2 STERILITY TESTING SERVICES 116
9.2.2.1 Need for sterility testing at each stage of drug development to propel growth 116
9.2.3 MYCOPLASMA TESTING SERVICES 119
9.2.3.1 Increasing focus on development of biologics and biosimilars to promote growth 119
9.2.4 ENDOTOXIN TESTING SERVICES 122
9.2.4.1 Stringent regulatory requirements to drive market 122
9.2.5 BIOBURDEN TESTING SERVICES 125
9.2.5.1 Rising adoption of advanced testing solutions for contamination risk mitigation to propel the growth 125
9.2.6 OTHER BST SERVICES 128
9.3 PRODUCTS 132
9.3.1 ASSAYS, KITS, AND REAGENTS 135
9.3.1.1 Detection kits 139
9.3.1.1.1 Expanding advanced biologics pipelines and faster QC workflows are lifting demand for high-sensitivity detection kits 139
9.3.1.2 Endotoxin testing reagents 142
9.3.1.2.1 Regulatory acceptance of recombinant methods and shift to simpler, animal-free QC workflows are accelerating demand for endotoxin testing reagents 142
9.3.1.3 Sterility testing media & kits 145
9.3.1.3.1 Rapid release needs and shift toward standardized aseptic QC strengthen demand for sterility testing media and kits 145
9.3.1.4 Bioburden enumeration 149
9.3.1.4.1 Stricter contamination control expectations and faster microbiology workflows drive demand for bioburden enumeration solutions 149
9.3.1.5 Other BST assays, kits, and reagents 152
9.3.2 INSTRUMENTS 155
9.3.2.1 Detection & imaging systems 159
9.3.2.1.1 Rapid molecular testing, automated microbiology, and standardized QC workflows are increasing the demand 159
9.3.2.2 Sequencing instruments 162
9.3.2.2.1 Wider adoption of NGS-based viral safety workflows and smaller, more accessible platforms support demand 162
9.3.2.3 Automated sterility testing systems 165
9.3.2.3.1 Shorter release timelines and wider adoption of rapid microbiology to drive growth 165
9.3.2.4 Other BST instruments 168
10 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE 172
10.1 INTRODUCTION 173
10.2 VIRUS SAFETY TESTS 173
10.2.1 GROWING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE SEGMENT GROWTH 173
10.3 STERILITY TESTS 177
10.3.1 MANDATORY STERILITY TESTING AT EACH STAGE IN DRUG DEVELOPMENT AND PRODUCTION PROCESS TO PROMOTE SEGMENT GROWTH 177
10.4 ENDOTOXIN TESTS 180
10.4.1 GROWING R&D ACTIVITIES FOR DEVELOPMENT OF BIOLOGICS TO PROMOTE THE GROWTH OF THE SEGMENT 180
10.5 MYCOPLASMA TESTS 183
10.5.1 RISING CONCERN FOR CELL CULTURE CONTAMINATION TO DRIVE THE SEGMENT GROWTH 183
10.6 BIOBURDEN TESTS 186
10.6.1 GROWING CONCERNS FOR DRUG SAFETY STANDARDS HAVE INCREASED THE DEMAND FOR MICROBIOLOGICAL BIOBURDEN TESTING IN THE BIOLOGICS INDUSTRY 186
10.7 RESIDUAL HCP & DNA DETECTION TESTS 190
10.7.1 STRINGENT REGULATORY GUIDELINES FOR BIOLOGIC DRUG MANUFACTURING TO CONTRIBUTE TO THE SEGMENT GROWTH 190
10.8 OTHER TESTS 193
11 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION 197
11.1 INTRODUCTION 198
11.2 MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS 198
11.2.1 GROWING REGULATORY APPROVALS FOR MONOCLONAL ANTIBODIES TO CONTRIBUTE TO THE MARKET SHARE 198
11.3 VACCINES 202
11.3.1 EXPANDING VACCINE PLATFORM COMPLEXITY AND STRICTER GLOBAL QUALITY EXPECTATIONS TO DRIVE MARKET GROWTH 202
11.4 CELLULAR & GENE THERAPY PRODUCTS 205
11.4.1 GROWING PRODUCT MANUFACTURING COMPLEXITY IS ACCELERATING DEMAND 205
11.5 BLOOD & BLOOD PRODUCTS 209
11.5.1 GROWING DEMAND FOR BLOOD PRODUCTS TO PROMOTE MARKET GROWTH 209
11.6 OTHER APPLICATIONS 212
12 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION 216
12.1 INTRODUCTION 217
12.2 MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING 217
12.2.1 EXPANDING ANTIBODY PIPELINES AND RISING BIOSIMILAR MANUFACTURING ARE DRIVING GROWTH 217
12.3 VACCINE SAFETY TESTING 221
12.3.1 EXPANSION OF VACCINE SAFETY TESTING DRIVEN BY ADVANCED PLATFORMS AND REGULATORY STRINGENCY 221
12.4 CELLULAR & GENE THERAPY SAFETY TESTING 224
12.4.1 EXPANDING ADVANCED THERAPY MANUFACTURING AND TIGHTER STERILITY REQUIREMENTS TO ACCELERATE DEMAND 224
12.5 BLOOD & BLOOD PRODUCT SAFETY TESTING 228
12.5.1 PLASMA PRODUCT SAFETY REQUIREMENTS AND NEW ASSAY APPROVALS TO DRIVE MARKET GROWTH 228
12.6 OTHER APPLICATIONS 231
13 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER 235
13.1 INTRODUCTION 236
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 236
13.2.1 RISING ADOPTION OF SAFETY TESTING PRODUCTS BY BIOPHARMA MANUFACTURERS 236
13.3 CROS & CDMOS 240
13.3.1 RISING OUTSOURCING OF BIOLOGICS DEVELOPMENT AND MANUFACTURING ACCELERATES MARKET GROWTH 240
13.4 ACADEMIC & RESEARCH INSTITUTES 243
13.4.1 EXPANDING TRANSLATIONAL BIOLOGICS RESEARCH AND EARLY-STAGE PLATFORM DEVELOPMENT DRIVES MARKET GROWTH 243
13.5 OTHER END USERS 246
14 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER 250
14.1 INTRODUCTION 251
14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 251
14.2.1 GROWING OUTSOURCING OF SAFETY TESTING SERVICES BY BIOPHARMA COMPANIES TO AID GROWTH 251
14.3 ACADEMIC & RESEARCH INSTITUTES 255
14.3.1 RISING TRANSLATIONAL RESEARCH IS DRIVING ADOPTION OF BIOLOGICS SAFETY TESTING SERVICES IN ACADEMIC INSTITUTES 255
14.4 OTHER END USERS 258
15 BIOLOGICS SAFETY TESTING MARKET, BY REGION 262
15.1 INTRODUCTION 263
15.2 NORTH AMERICA 263
15.2.1 US 269
15.2.1.1 Leading biopharma industry, federal funding, mature ecosystem, and biologics development activity to propel market growth 269
15.2.2 CANADA 273
15.2.2.1 Investments for expanding biomanufacturing capacity to propel market growth 273
15.3 EUROPE 279
15.3.1 GERMANY 284
15.3.1.1 Expansion initiatives by key market players to support market growth 284
15.3.2 UK 289
15.3.2.1 Emphasis on vaccine manufacturing and biotech R&D to drive market 289
15.3.3 FRANCE 293
15.3.3.1 Strong government funding driving biologics innovation and testing demand 293
15.3.4 ITALY 298
15.3.4.1 Manufacturing investment and strong R&D intensity support market growth 298
15.3.5 SPAIN 302
15.3.5.1 Growing expansion of biotech companies and increasing R&D expenditure to drive market 302
15.3.6 REST OF EUROPE 307
15.4 ASIA PACIFIC 312
15.4.1 CHINA 318
15.4.1.1 Rising biologics development driving market growth 318
15.4.2 JAPAN 323
15.4.2.1 Government initiatives and expansion of biopharma companies to boost market 323
15.4.3 INDIA 327
15.4.3.1 Expanding biologics capabilities and rising demand for targeted oncology therapies drive market growth 327
15.4.4 SOUTH KOREA 332
15.4.4.1 Growing focus on advancing bioprocessing sector to drive market 332
15.4.5 AUSTRALIA 336
15.4.5.1 Strong regulatory framework, clinical innovation, and global partnerships drive market growth 336
15.4.6 REST OF ASIA PACIFIC 341
15.5 LATIN AMERICA 345
15.5.1 BRAZIL 350
15.5.1.1 Expanding biologics manufacturing investment and rising clinical development activity are driving market growth 350
15.5.2 MEXICO 355
15.5.2.1 Increasing government support for biopharmaceutical production to drive market 355
15.5.3 REST OF LATIN AMERICA 359
15.6 MIDDLE EAST 364
15.6.1 GCC COUNTRIES 369
15.6.1.1 Saudi Arabia 374
15.6.1.1.1 Increasing healthcare expenditure and rising focus of key players on expansion to support growth 374
15.6.1.2 United Arab Emirates 378
15.6.1.2.1 Developing biopharma sector to drive market 378
15.6.1.3 Rest of GCC countries 383
15.6.2 REST OF MIDDLE EAST 387
15.7 AFRICA 392
15.7.1 RISING AWARENESS AND COLLABORATIVE INITIATIVES TO DRIVE ADOPTION 392
16 COMPETITIVE LANDSCAPE 397
16.1 INTRODUCTION 397
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 397
16.3 REVENUE ANALYSIS 399
16.4 MARKET SHARE ANALYSIS 400
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 403
16.5.1 STARS 403
16.5.2 EMERGING LEADERS 403
16.5.3 PERVASIVE PLAYERS 404
16.5.4 PARTICIPANTS 404
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 405
16.5.5.1 Company footprint 405
16.5.5.2 Region footprint 406
16.5.5.3 Offering footprint 407
16.5.5.4 Test type footprint 408
16.5.5.5 Application footprint of companies 410
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 411
16.6.1 PROGRESSIVE COMPANIES 411
16.6.2 RESPONSIVE COMPANIES 411
16.6.3 DYNAMIC COMPANIES 411
16.6.4 STARTING BLOCKS 411
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 413
16.6.5.1 Detailed list of key startups/SMEs 413
16.6.5.2 Competitive benchmarking of key startups/SMEs 414
16.7 COMPANY VALUATION & FINANCIAL METRICS 415
16.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 417
16.9 COMPETITIVE SCENARIO 417
16.9.1 PRODUCT LAUNCHES 418
16.9.2 DEALS 418
16.9.3 EXPANSIONS 419
17 COMPANY PROFILES 420
17.1 MAJOR PALYER 420
17.1.1 THERMO FISHER SCIENTIFIC INC. 420
17.1.1.1 Business overview 420
17.1.1.2 Products/Services/Solutions offered 422
17.1.1.3 Recent developments 424
17.1.1.3.1 Service launches 424
17.1.1.3.2 Deals 424
17.1.1.3.3 Expansions 424
17.1.1.4 MnM view 425
17.1.1.4.1 Key strengths 425
17.1.1.4.2 Strategic choices 425
17.1.1.4.3 Weaknesses and competitive threats 425
17.1.2 CHARLES RIVER LABORATORIES 426
17.1.2.1 Business overview 426
17.1.2.2 Products/Services/Solutions offered 427
17.1.2.3 Recent developments 429
17.1.2.3.1 Product and service launches 429
17.1.2.3.2 Deals 430
17.1.2.4 MnM view 430
17.1.2.4.1 Key strengths 430
17.1.2.4.2 Strategic choices 430
17.1.2.4.3 Weaknesses and competitive threats 430
17.1.3 LABORATORY CORPORATION OF AMERICA HOLDINGS 431
17.1.3.1 Business overview 431
17.1.3.2 Products/Services/Solutions offered 433
17.1.3.3 Recent developments 433
17.1.3.3.1 Deals 433
17.1.3.3.2 Expansions 434
17.1.3.4 MnM view 434
17.1.3.4.1 Key strengths 434
17.1.3.4.2 Strategic choices 434
17.1.3.4.3 Weaknesses and competitive threats 434
17.1.4 F. HOFFMANN-LA ROCHE LTD. 435
17.1.4.1 Business overview 435
17.1.4.2 Products/Services/Solutions offered 436
17.1.4.3 Recent developments 437
17.1.4.3.1 Product launches 437
17.1.4.3.2 Expansions 437
17.1.4.4 MnM view 438
17.1.4.4.1 Key strengths 438
17.1.4.4.2 Strategic choices 438
17.1.4.4.3 Weaknesses and competitive threats 438
17.1.5 MERCK KGAA 439
17.1.5.1 Business overview 439
17.1.5.2 Products/Services/Solutions offered 441
17.1.5.3 Recent developments 442
17.1.5.3.1 Expansions 442
17.1.5.4 MnM view 443
17.1.5.4.1 Key strengths 443
17.1.5.4.2 Strategic choices 443
17.1.5.4.3 Weaknesses and competitive threats 443
17.1.6 SARTORIUS AG 444
17.1.6.1 Business overview 444
17.1.6.2 Products/Services/Solutions offered 445
17.1.6.3 Recent developments 446
17.1.6.3.1 Product launches 446
17.1.7 LONZA 447
17.1.7.1 Business overview 447
17.1.7.2 Products/Services/Solutions offered 448
17.1.7.3 Recent developments 451
17.1.7.3.1 Product launches 451
17.1.7.3.2 Deals 451
17.1.8 FUJIFILM CORPORATION 452
17.1.8.1 Business overview 452
17.1.8.2 Products/Services/Solutions offered 453
17.1.8.3 Recent developments 455
17.1.8.3.1 Expansions 455
17.1.9 BIOM?RIEUX 456
17.1.9.1 Business overview 456
17.1.9.2 Products/Services/Solutions offered 458
17.1.9.3 Recent developments 459
17.1.9.3.1 Product launches 459
17.1.9.3.2 Deals 459
17.1.10 MARAVAI LIFESCIENCES 460
17.1.10.1 Business overview 460
17.1.10.2 Products/Services/Solutions offered 461
17.1.10.3 Recent developments 462
17.1.10.3.1 Deals 462
17.1.11 WUXI APPTEC 463
17.1.11.1 Business overview 463
17.1.11.2 Products/Services/Solutions offered 465
17.1.12 SGS SOCI?T? G?N?RALE DE SURVEILLANCE SA 466
17.1.12.1 Business overview 466
17.1.12.2 Products/Services/Solutions offered 468
17.1.12.3 Recent developments 469
17.1.12.3.1 Service launches 469
17.1.12.3.2 Expansions 469
17.1.13 SOTERA HEALTH 470
17.1.13.1 Business overview 470
17.1.13.2 Products/Services/Solutions offered 472
17.1.13.3 Recent developments 472
17.1.13.3.1 Service launches 472
17.1.13.3.2 Expansions 472
17.1.14 SAMSUNG BIOLOGICS 473
17.1.14.1 Business overview 473
17.1.14.2 Products/Services/Solutions offered 474
17.1.14.3 Recent developments 474
17.1.14.3.1 Deals 474
17.1.14.3.2 Expansions 475
17.1.15 GENSCRIPT 476
17.1.15.1 Business overview 476
17.1.15.2 Products/Services/Solutions offered 478
17.1.16 AGILENT TECHNOLOGIES, INC. 479
17.1.16.1 Business overview 479
17.1.16.2 Products/Services/Solutions offered 480
17.1.17 SYNGENE INTERNATIONAL LIMITED 482
17.1.17.1 Business overview 482
17.1.17.2 Products/Services/Solutions offered 484
17.1.18 EUROFINS SCIENTIFIC 485
17.1.18.1 Business overview 485
17.1.18.2 Products/Services/Solutions offered 487
17.1.18.3 Recent developments 488
17.1.18.3.1 Service launches 488
17.1.18.3.2 Expansions 488
17.1.19 BIO-RAD LABORATORIES, INC. 489
17.1.19.1 Business overview 489
17.1.19.2 Products/Services/Solutions offered 491
17.1.19.3 Recent developments 492
17.1.19.3.1 Product launches 492
17.1.19.3.2 Deals 492
17.1.20 QIAGEN 493
17.1.20.1 Business overview 493
17.1.20.2 Products/Services/Solutions offered 495
17.1.20.3 Recent developments 495
17.1.20.3.1 Product launches 495
17.2 OTHER PLAYERS 496
17.2.1 PROMEGA CORPORATION 496
17.2.2 CATALENT, INC. 497
17.2.3 ASSOCIATES OF CAPE COD, INC. 498
17.2.4 CLEAN BIOLOGICS 499
17.2.5 PATHOQUEST 500
17.2.6 PACIFIC BIOLABS 501
17.2.7 ARL BIO PHARMA, INC. 502
17.2.8 FRONTAGE LABS 503
17.2.9 CREATIVE BIOGENE 504
17.2.10 ADVAXIA BIOLOGICS 505
18 RESEARCH METHODOLOGY 506
18.1 RESEARCH DATA 506
18.1.1 SECONDARY DATA 507
18.1.2 PRIMARY DATA 507
18.2 MARKET ESTIMATION METHODOLOGY 509
18.2.1 MARKET SIZE ESTIMATION 509
18.2.2 INSIGHTS OF PRIMARY EXPERTS 512
18.2.3 TOP-DOWN APPROACH 512
18.3 MARKET GROWTH RATE PROJECTIONS 513
18.4 MARKET BREAKDOWN AND DATA TRIANGULATION 515
18.5 RESEARCH ASSUMPTIONS 516
18.6 RESEARCH LIMITATIONS 517
18.7 RISK ANALYSIS 517
19 APPENDIX 518
19.1 DISCUSSION GUIDE 518
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 522
19.3 CUSTOMIZATION OPTIONS 524
19.4 RELATED REPORTS 525
19.5 AUTHOR DETAILS 526

ページTOPに戻る

List of Tables/Graphs

TABLE 1 BIOLOGICS SAFETY TESTING MARKET: IMPACT ANALYSIS 61
TABLE 2 BIOLOGICS SAFETY TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 68
TABLE 3 BIOLOGICS SAFETY TESTING MARKET: ROLE IN ECOSYSTEM 73
TABLE 4 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023?2025 (USD) 75
TABLE 5 INDICATIVE SELLING PRICE OF KEY PRODUCTS, BY REGION, 2025 76
TABLE 6 BIOLOGICS SAFETY TESTING MARKET: KEY CONFERENCES & EVENTS, 2026?2027 77
TABLE 7 US-ADJUSTED RECIPROCAL TARIFF RATES 80
TABLE 8 APPLICATIONS OF PCR IN BIOLOGICS SAFETY TESTING 85
TABLE 9 INDICATIVE LIST OF PATENTS IN BIOLOGICS SAFETY TESTING MARKET, 2025 89
TABLE 10 CASE STUDIES OF AI IMPLEMENTATION IN BIOLOGICS SAFETY TESTING MARKET 91
TABLE 11 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN BIOLOGICS SAFETY TESTING MARKET 92
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
TABLE 15 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
TABLE 16 COUNTRY-WISE REGULATORY SCENARIO FOR BIOLOGICS SAFETY TESTING MANUFACTURERS 98
TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%) 103
TABLE 18 KEY BUYING CRITERIA, BY END USER 104
TABLE 19 BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024?2031 (USD MILLION) 108
TABLE 20 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024?2031 (USD MILLION) 109
TABLE 21 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY REGION, 2024?2031 (USD MILLION) 109
TABLE 22 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 110
TABLE 23 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 110
TABLE 24 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 111
TABLE 25 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 111
TABLE 26 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY REGION, 2024?2031 (USD MILLION) 111
TABLE 27 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 112
TABLE 28 VIRUS SAFETY TESTING SERVICES MARKET, BY REGION, 2024?2031 (USD MILLION) 113
TABLE 29 NORTH AMERICA: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 113
TABLE 30 EUROPE: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 114
TABLE 31 ASIA PACIFIC: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 114
TABLE 32 LATIN AMERICA: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 115
TABLE 33 MIDDLE EAST: VIRUS SAFETY TESTING SERVICES MARKET, BY REGION, 2024?2031 (USD MILLION) 115
TABLE 34 GCC COUNTRIES: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 115
TABLE 35 STERILITY TESTING SERVICES MARKET, BY REGION, 2024?2031 (USD MILLION) 116
TABLE 36 NORTH AMERICA: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 116
TABLE 37 EUROPE: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 117
TABLE 38 ASIA PACIFIC: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 117
TABLE 39 LATIN AMERICA: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 118
TABLE 40 MIDDLE EAST: STERILITY TESTING SERVICES MARKET, BY REGION, 2024?2031 (USD MILLION) 118
TABLE 41 GCC COUNTRIES: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 118
TABLE 42 MYCOPLASMA TESTING SERVICES MARKET, BY REGION, 2024?2031 (USD MILLION) 119
TABLE 43 NORTH AMERICA: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 120
TABLE 44 EUROPE: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 120
TABLE 45 ASIA PACIFIC: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 121
TABLE 46 LATIN AMERICA: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 121
TABLE 47 MIDDLE EAST: MYCOPLASMA TESTING SERVICES MARKET, BY REGION, 2024?2031 (USD MILLION) 121
TABLE 48 GCC COUNTRIES: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 122
TABLE 49 ENDOTOXIN TESTING SERVICES MARKET, BY REGION, 2024?2031 (USD MILLION) 122
TABLE 50 NORTH AMERICA: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 123
TABLE 51 EUROPE: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 123
TABLE 52 ASIA PACIFIC: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 124
TABLE 53 LATIN AMERICA: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 124
TABLE 54 MIDDLE EAST: ENDOTOXIN TESTING SERVICES MARKET, BY REGION, 2024?2031 (USD MILLION) 125
TABLE 55 GCC COUNTRIES: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 125
TABLE 56 BIOBURDEN TESTING SERVICES MARKET, BY REGION, 2024?2031 (USD MILLION) 126
TABLE 57 NORTH AMERICA: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 126
TABLE 58 EUROPE: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 127
TABLE 59 ASIA PACIFIC: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 127
TABLE 60 LATIN AMERICA: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 128
TABLE 61 MIDDLE EAST: BIOBURDEN TESTING SERVICES MARKET, BY REGION, 2024?2031 (USD MILLION) 128
TABLE 62 GCC COUNTRIES: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 128
TABLE 63 OTHER BST SERVICES MARKET, BY REGION, 2024?2031 (USD MILLION) 129
TABLE 64 NORTH AMERICA: OTHER BST SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 129
TABLE 65 EUROPE: OTHER BST SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 130
TABLE 66 ASIA PACIFIC: OTHER BST SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 130
TABLE 67 LATIN AMERICA: OTHER BST SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 131
TABLE 68 MIDDLE EAST: OTHER BST SERVICES MARKET, BY REGION, 2024?2031 (USD MILLION) 131
TABLE 69 GCC COUNTRIES: OTHER BST SERVICES MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 131
TABLE 70 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024?2031 (USD MILLION) 132
TABLE 71 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY REGION, 2024?2031 (USD MILLION) 132
TABLE 72 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 133
TABLE 73 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 133
TABLE 74 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 134
TABLE 75 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 134
TABLE 76 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY REGION, 2024?2031 (USD MILLION) 134
TABLE 77 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 134
TABLE 78 BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024?2031 (USD MILLION) 135
TABLE 79 BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY REGION, 2024?2031 (USD MILLION) 136
TABLE 80 NORTH AMERICA: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 136
TABLE 81 EUROPE: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 137
TABLE 82 ASIA PACIFIC: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 137
TABLE 83 LATIN AMERICA: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 138
TABLE 84 MIDDLE EAST: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY REGION, 2024?2031 (USD MILLION) 138
TABLE 85 GCC COUNTRIES: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 138
TABLE 86 DETECTION KITS MARKET, BY REGION, 2024?2031 (USD MILLION) 139
TABLE 87 NORTH AMERICA: DETECTION KITS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 140
TABLE 88 EUROPE: DETECTION KITS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 140
TABLE 89 ASIA PACIFIC: DETECTION KITS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 140
TABLE 90 LATIN AMERICA: DETECTION KITS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 141
TABLE 91 MIDDLE EAST: DETECTION KITS MARKET, BY REGION, 2024?2031 (USD MILLION) 141
TABLE 92 GCC COUNTRIES: DETECTION KITS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 141
TABLE 93 ENDOTOXIN TESTING REAGENTS MARKET, BY REGION, 2024?2031 (USD MILLION) 142
TABLE 94 NORTH AMERICA: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 143
TABLE 95 EUROPE: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 143
TABLE 96 ASIA PACIFIC: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 144
TABLE 97 LATIN AMERICA: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 144
TABLE 98 MIDDLE EAST: ENDOTOXIN TESTING REAGENTS MARKET, BY REGION, 2024?2031 (USD MILLION) 144
TABLE 99 GCC COUNTRIES: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 145
TABLE 100 STERILITY TESTING MEDIA & KITS MARKET, BY REGION, 2024?2031 (USD MILLION) 146
TABLE 101 NORTH AMERICA: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 146
TABLE 102 EUROPE: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 147
TABLE 103 ASIA PACIFIC: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 147
TABLE 104 LATIN AMERICA: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 148
TABLE 105 MIDDLE EAST: STERILITY TESTING MEDIA & KITS MARKET, BY REGION, 2024?2031 (USD MILLION) 148
TABLE 106 GCC COUNTRIES: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 148
TABLE 107 BIOBURDEN ENUMERATION MARKET, BY REGION, 2024?2031 (USD MILLION) 149
TABLE 108 NORTH AMERICA: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 150
TABLE 109 EUROPE: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 150
TABLE 110 ASIA PACIFIC: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 151
TABLE 111 LATIN AMERICA: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 151
TABLE 112 MIDDLE EAST: BIOBURDEN ENUMERATION MARKET, BY REGION, 2024?2031 (USD MILLION) 151
TABLE 113 GCC COUNTRIES: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 152
TABLE 114 OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY REGION, 2024?2031 (USD MILLION) 152
TABLE 115 NORTH AMERICA: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 153
TABLE 116 EUROPE: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 153
TABLE 117 ASIA PACIFIC: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 154
TABLE 118 LATIN AMERICA: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 154
TABLE 119 MIDDLE EAST: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY REGION, 2024?2031 (USD MILLION) 154
TABLE 120 GCC COUNTRIES: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 155
TABLE 121 BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024?2031 (USD MILLION) 155
TABLE 122 BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY REGION, 2024?2031 (USD MILLION) 156
TABLE 123 NORTH AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 156
TABLE 124 EUROPE: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 157
TABLE 125 ASIA PACIFIC: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 157
TABLE 126 LATIN AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 158
TABLE 127 MIDDLE EAST: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY REGION, 2024?2031 (USD MILLION) 158
TABLE 128 GCC COUNTRIES: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 158
TABLE 129 DETECTION & IMAGING SYSTEMS MARKET, BY REGION, 2024?2031 (USD MILLION) 159
TABLE 130 NORTH AMERICA: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 160
TABLE 131 EUROPE: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 160
TABLE 132 ASIA PACIFIC: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 161
TABLE 133 LATIN AMERICA: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 161
TABLE 134 MIDDLE EAST: DETECTION & IMAGING SYSTEMS MARKET, BY REGION, 2024?2031 (USD MILLION) 161
TABLE 135 GCC COUNTRIES: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 162
TABLE 136 SEQUENCING INSTRUMENTS MARKET, BY REGION, 2024?2031 (USD MILLION) 162
TABLE 137 NORTH AMERICA: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 163
TABLE 138 EUROPE: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 163
TABLE 139 ASIA PACIFIC: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 164
TABLE 140 LATIN AMERICA: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 164
TABLE 141 MIDDLE EAST: SEQUENCING INSTRUMENTS MARKET, BY REGION, 2024?2031 (USD MILLION) 164
TABLE 142 GCC COUNTRIES: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 165
TABLE 143 AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY REGION, 2024?2031 (USD MILLION) 165
TABLE 144 NORTH AMERICA: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 166
TABLE 145 EUROPE: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 166
TABLE 146 ASIA PACIFIC: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 167
TABLE 147 LATIN AMERICA: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 167
TABLE 148 MIDDLE EAST: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY REGION, 2024?2031 (USD MILLION) 167
TABLE 149 GCC COUNTRIES: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 168
TABLE 150 OTHER BST INSTRUMENTS MARKET, BY REGION, 2024?2031 (USD MILLION) 168
TABLE 151 NORTH AMERICA: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 169
TABLE 152 EUROPE: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 169
TABLE 153 ASIA PACIFIC: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 170
TABLE 154 LATIN AMERICA: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 170
TABLE 155 MIDDLE EAST: OTHER BST INSTRUMENTS MARKET, BY REGION, 2024?2031 (USD MILLION) 170
TABLE 156 GCC COUNTRIES: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 171
TABLE 157 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024?2031 (USD MILLION) 173
TABLE 158 VIRUS SAFETY TESTS MARKET, BY REGION, 2024?2031 (USD MILLION) 174
TABLE 159 NORTH AMERICA: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 174
TABLE 160 EUROPE: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 175
TABLE 161 ASIA PACIFIC: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 175
TABLE 162 LATIN AMERICA: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 176
TABLE 163 MIDDLE EAST: VIRUS SAFETY TESTS MARKET, BY REGION, 2024?2031 (USD MILLION) 176
TABLE 164 GCC COUNTRIES: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 176
TABLE 165 STERILITY TESTS MARKET, BY REGION, 2024?2031 (USD MILLION) 177
TABLE 166 NORTH AMERICA: STERILITY TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 178
TABLE 167 EUROPE: STERILITY TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 178
TABLE 168 ASIA PACIFIC: STERILITY TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 179
TABLE 169 LATIN AMERICA: STERILITY TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 179
TABLE 170 MIDDLE EAST: STERILITY TESTS MARKET, BY REGION, 2024?2031 (USD MILLION) 179
TABLE 171 GCC COUNTRIES: STERILITY TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 180
TABLE 172 ENDOTOXIN TESTS MARKET, BY REGION, 2024?2031 (USD MILLION) 181
TABLE 173 NORTH AMERICA: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 181
TABLE 174 EUROPE: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 182
TABLE 175 ASIA PACIFIC: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 182
TABLE 176 LATIN AMERICA: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 182
TABLE 177 MIDDLE EAST: ENDOTOXIN TESTS MARKET, BY REGION, 2024?2031 (USD MILLION) 183
TABLE 178 GCC COUNTRIES: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 183
TABLE 179 MYCOPLASMA TESTS MARKET, BY REGION, 2024?2031 (USD MILLION) 184
TABLE 180 NORTH AMERICA: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 184
TABLE 181 EUROPE: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 185
TABLE 182 ASIA PACIFIC: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 185
TABLE 183 LATIN AMERICA: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 185
TABLE 184 MIDDLE EAST: MYCOPLASMA TESTS MARKET, BY REGION, 2024?2031 (USD MILLION) 186
TABLE 185 GCC COUNTRIES: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 186
TABLE 186 BIOBURDEN TESTS MARKET, BY REGION, 2024?2031 (USD MILLION) 187
TABLE 187 NORTH AMERICA: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 187
TABLE 188 EUROPE: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 188
TABLE 189 ASIA PACIFIC: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 188
TABLE 190 LATIN AMERICA: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 189
TABLE 191 MIDDLE EAST: BIOBURDEN TESTS MARKET, BY REGION, 2024?2031 (USD MILLION) 189
TABLE 192 GCC COUNTRIES: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 189
TABLE 193 RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY REGION, 2024?2031 (USD MILLION) 190
TABLE 194 NORTH AMERICA: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 191
TABLE 195 EUROPE: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 191
TABLE 196 ASIA PACIFIC: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 192
TABLE 197 LATIN AMERICA: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 192
TABLE 198 MIDDLE EAST: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY REGION, 2024?2031 (USD MILLION) 192
TABLE 199 GCC COUNTRIES: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 193
TABLE 200 OTHER TESTS MARKET, BY REGION, 2024?2031 (USD MILLION) 193
TABLE 201 NORTH AMERICA: OTHER TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 194
TABLE 202 EUROPE: OTHER TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 194
TABLE 203 ASIA PACIFIC: OTHER TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 195
TABLE 204 LATIN AMERICA: OTHER TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 195
TABLE 205 MIDDLE EAST: OTHER TESTS MARKET, BY REGION, 2024?2031 (USD MILLION) 195
TABLE 206 GCC COUNTRIES: OTHER BST TESTS MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 196
TABLE 207 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024?2031 (USD MILLION) 198
TABLE 208 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY REGION, 2024?2031 (USD MILLION) 199
TABLE 209 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024?2031 (USD MILLION) 199
TABLE 210 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024?2031 (USD MILLION) 200
TABLE 211 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024?2031 (USD MILLION) 200
TABLE 212 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024?2031 (USD MILLION) 201
TABLE 213 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY REGION, 2024?2031 (USD MILLION) 201
TABLE 214 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024?2031 (USD MILLION) 201
TABLE 215 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY REGION, 2024?2031 (USD MILLION) 202
TABLE 216 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024?2031 (USD MILLION) 203
TABLE 217 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024?2031 (USD MILLION) 203
TABLE 218 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024?2031 (USD MILLION) 204
TABLE 219 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024?2031 (USD MILLION) 204
TABLE 220 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY REGION, 2024?2031 (USD MILLION) 204
TABLE 221 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024?2031 (USD MILLION) 205
TABLE 222 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY REGION, 2024?2031 (USD MILLION) 206
TABLE 223 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024?2031 (USD MILLION) 206
TABLE 224 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024?2031 (USD MILLION) 207
TABLE 225 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024?2031 (USD MILLION) 207
TABLE 226 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024?2031 (USD MILLION) 208
TABLE 227 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY REGION, 2024?2031 (USD MILLION) 208
TABLE 228 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024?2031 (USD MILLION) 208
TABLE 229 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY REGION, 2024?2031 (USD MILLION) 209
TABLE 230 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024?2031 (USD MILLION) 210
TABLE 231 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024?2031 (USD MILLION) 210
TABLE 232 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024?2031 (USD MILLION) 211
TABLE 233 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024?2031 (USD MILLION) 211
TABLE 234 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY REGION, 2024?2031 (USD MILLION) 211
TABLE 235 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024?2031 (USD MILLION) 212
TABLE 236 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024?2031 (USD MILLION) 212
TABLE 237 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024?2031 (USD MILLION) 213
TABLE 238 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024?2031 (USD MILLION) 213
TABLE 239 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024?2031 (USD MILLION) 214
TABLE 240 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024?2031 (USD MILLION) 214
TABLE 241 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024?2031 (USD MILLION) 215
TABLE 242 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024?2031 (USD MILLION) 215
TABLE 243 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024?2031 (USD MILLION) 217
TABLE 244 BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY REGION, 2024?2031 (USD MILLION) 218
TABLE 245 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN, BY COUNTRY, 2024?2031 (USD MILLION) 218
TABLE 246 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 219
TABLE 247 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 219
TABLE 248 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 220
TABLE 249 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY REGION, 2024?2031 (USD MILLION) 220
TABLE 250 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 220
TABLE 251 BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY REGION, 2024?2031 (USD MILLION) 221
TABLE 252 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 222
TABLE 253 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 222
TABLE 254 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 223
TABLE 255 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 223
TABLE 256 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY REGION, 2024?2031 (USD MILLION) 223
TABLE 257 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 224
TABLE 258 BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY REGION, 2024?2031 (USD MILLION) 225
TABLE 259 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 225
TABLE 260 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 226
TABLE 261 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 226
TABLE 262 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 227
TABLE 263 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY REGION, 2024?2031 (USD MILLION) 227
TABLE 264 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 227
TABLE 265 BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY REGION, 2024?2031 (USD MILLION) 228
TABLE 266 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 229
TABLE 267 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 229
TABLE 268 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 230
TABLE 269 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 230
TABLE 270 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY REGION, 2024?2031 (USD MILLION) 230
TABLE 271 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024?2031 (USD MILLION) 231
TABLE 272 BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY REGION, 2024?2031 (USD MILLION) 232
TABLE 273 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024?2031 (USD MILLION) 232
TABLE 274 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024?2031 (USD MILLION) 233
TABLE 275 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024?2031 (USD MILLION) 233
TABLE 276 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024?2031 (USD MILLION) 234
TABLE 277 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY REGION, 2024?2031 (USD MILLION) 234
TABLE 278 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024?2031 (USD MILLION) 234
TABLE 279 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024?2031 (USD MILLION) 236
TABLE 280 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024?2031 (USD MILLION) 237
TABLE 281 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024?2031 (USD MILLION) 237
TABLE 282 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024?2031 (USD MILLION) 238
TABLE 283 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024?2031 (USD MILLION) 238
TABLE 284 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024?2031 (USD MILLION) 239
TABLE 285 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024?2031 (USD MILLION) 239
TABLE 286 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024?2031 (USD MILLION) 239
TABLE 287 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024?2031 (USD MILLION) 240
TABLE 288 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024?2031 (USD MILLION) 240
TABLE 289 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024?2031 (USD MILLION) 241
TABLE 290 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024?2031 (USD MILLION) 241
TABLE 291 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024?2031 (USD MILLION) 242
TABLE 292 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024?2031 (USD MILLION) 242
TABLE 293 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024?2031 (USD MILLION) 242
TABLE 294 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024?2031 (USD MILLION) 243
TABLE 295 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024?2031 (USD MILLION) 244
TABLE 296 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024?2031 (USD MILLION) 244
TABLE 297 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024?2031 (USD MILLION) 245
TABLE 298 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024?2031 (USD MILLION) 245
TABLE 299 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024?2031 (USD MILLION) 245
TABLE 300 GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024?2031 (USD MILLION) 246
TABLE 301 BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2024?2031 (USD MILLION) 246
TABLE 302 NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024?2031 (USD MILLION) 247
TABLE 303 EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024?2031 (USD MILLION) 247
TABLE 304 ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024?2031 (USD MILLION) 248
TABLE 305 LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024?2031 (USD MILLION) 248
TABLE 306 MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2024?2031 (USD MILLION) 248TABLE 307 GCC COUNTRIES: BIOLOG